-
Ultimovacs ASA: Fourth quarter 2021 result presentation
-
Ultimovacs ASA: Invitation to fourth quarter 2021 results webcast presentation
-
Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study
-
First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer
-
Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification for close associate
-
Ultimovacs ASA: Third quarter 2021 result presentation
-
Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma
